European Society of Cardiology
Pharmacological BP reduction effective for lowering CV event risk regardless of age
Lowering BP through medication reduced risk for CV events across almost all age groups, suggesting age-related BP thresholds should be removed from guidelines, researchers reported at the European Society of Cardiology Congress.
Daily coffee intake may improve cardiac function, lower risk for mortality, stroke
Daily coffee consumption may improve cardiac function and up to three cups per day was associated with lower risk for CV and all-cause death and stroke, according to data presented at the European Society of Cardiology Congress.
Fibrosis ablation not superior to PVI, but promising in early stages of atrial myopathy
In patients with persistent atrial fibrillation, a strategy of ablation based on MRI assessment of atrial fibrosis was not superior to pulmonary vein isolation for prevention of arrhythmia recurrence, researchers reported.
AED-equipped drones can arrive minutes ahead of EMS for out-of-hospital cardiac arrest
Drones successfully delivered automated external defibrillators to the locations of suspected out-of-hospital cardiac arrests, according to a speaker at the European Society of Cardiology Congress.
Upper GI bleeding common after acute MI, linked to poor prognosis
In patients with acute MI, upper gastrointestinal bleeding occurred in 1.5% within 1 year and was associated with poor outcomes, researchers reported at the European Society of Cardiology Congress.
Dapagliflozin reduces risk for ventricular arrhythmia, cardiac arrest, sudden death
Compared with placebo, dapagliflozin reduced risk for ventricular arrhythmias, cardiac arrest and sudden death, according to new data from the DAPA-HF trial.
STOPDAPT-2 ACS trial inconclusive for 1- vs. 12-month DAPT after PCI and DES implantation
Despite fewer bleeding events, 1-month dual antiplatelet therapy with clopidogrel failed to prove noninferiority vs. 12-month DAPT after PCI and stent implantation for ACS, according to a presenter.
Valsartan stunts disease progression in early-stage sarcomeric hypertrophic cardiomyopathy
In patients with early-stage sarcomeric hypertrophic cardiomyopathy, valsartan improved certain parameters of disease progression compared with placebo, researchers reported at the European Society of Cardiology Congress.
‘Quadpill’ strategy effective, safe, tolerable vs. monotherapy for BP lowering
Use of a “quadpill” capsule containing quarter doses of four antihypertensive medications conferred greater BP reductions compared with monotherapy, with similar safety and tolerability, a speaker reported.
ESC guideline offers individualized, stepwise approach to CVD prevention
The new European Society of Cardiology guideline on CVD prevention in clinical practice offers a stepwise approach to managing CVD risk in various populations,